Artificial Intelligence-Enhanced Management for Coronary Heart Disease (AIM-CHD) : Impact on Cholesterol and Other CHD Risk Factors

NACompletedINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

November 23, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Secondary Prevention of Coronary Heart Disease
Interventions
COMBINATION_PRODUCT

AIM-CHD Mobile Health Intervention

The AIM-CHD platform synchronizes data from hospitalization records, questionnaires, AI-powered voice follow-ups, and wearable devices to perform risk stratification and manage uncontrolled risk factors. It provides individualized follow-up plans, medication reminders, and lifestyle education, with real-time assessments of vital health metrics to prompt necessary in-person consultations. The app offers online consultation access and emergency services through Fuwai Hospital. Additionally, it delivers personalized patient education, aligning with the latest clinical guidelines.

COMBINATION_PRODUCT

Usual post-discharge care

Usual post-discharge care includes oral and written instructions on sustained pharmacotherapy regimens, recommended follow-up frequency, and lifestyle modifications.

Trial Locations (1)

100037

Fuwai Hospital, Chinese Academy of Medical Sciences/National Center for Cardiovascular Diseases, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV

NCT06686056 - Artificial Intelligence-Enhanced Management for Coronary Heart Disease (AIM-CHD) : Impact on Cholesterol and Other CHD Risk Factors | Biotech Hunter | Biotech Hunter